Free UK shipping
Results in under 14 days
UK lab
10% Off All Tests - January 2026
Aripiprazole belongs to the newest class of antipsychotic medicines. Older antipsychotics tend to block dopamine strongly, which can cause Parkinson’s-like movement problems, whereas aripiprazole is much improved in this domain.
Aripiprazole works differently. It acts as a partial agonist at dopamine receptors, which means it does not fully block or fully stimulate dopamine. Instead, it helps bring dopamine signalling back toward balance. In areas of the brain where dopamine is too high, it reduces activity. In areas where dopamine is too low, it supports activity. Because of this stabilising effect, aripiprazole is sometimes described as a “smarter” or more selective antipsychotic.
This mechanism contributes to a lower chance of movement-related side effects, fewer metabolic problems than older medicines and more stable emotional function for many people.
Aripiprazole affects dopamine and serotonin systems in a more flexible way than other antipsychotics. This often leads to better tolerability, but each person responds differently and the medicine still requires monitoring.
Compared with older antipsychotics, aripiprazole is less likely to cause:
Some people experience far fewer negative sensations on aripiprazole and find it easier to stay on treatment for the long term. That said, side effects can still happen and there is important personal variation.
Alongside its favourable profile, aripiprazole can still cause:
Sharing any noticeable changes in mood, motivation, behaviour or sleep with your clinician helps ensure the dose is right for you.
Brain imaging research shows that aripiprazole adapts the level of dopamine receptor activity depending on the baseline activity in each region. This is thought to contribute to improvement in hallucinations and delusions as well as better social functioning, emotional engagement and motivation.
Aripiprazole also influences GABA and glutamate activity in the prefrontal cortex, which may support clearer thinking and improved social interaction.
Beyond schizophrenia and mania, aripiprazole has been used in other mental health conditions, including bipolar disorder, depression (as an add-on treatment), Tourette syndrome and irritability in autism. Not all of these uses are licensed in the UK, but they reflect the broader research on the medicine’s mechanism.
Although aripiprazole has attractive pharmacological features, large studies show that antipsychotics have broadly similar effectiveness overall. What differs is the individual experience. Some people thrive on aripiprazole. Others benefit more from a different medicine. Choosing the right antipsychotic is a shared decision between clinician and patient, based on symptoms, side effects, lifestyle and personal preference.
Explore PGX for Mental HealthManaging schizophrenia and mania
Aripiprazole is prescribed in the UK for schizophrenia and for managing episodes of mania. It is often chosen when a clinician wants a treatment that has fewer movement problems and a lighter metabolic burden than many older antipsychotics.
Most people take aripiprazole orally once a day. The dose is increased slowly to find the right balance between symptom improvement and tolerability. Your clinician may also consider your CYP2D6 genetic profile, because people who metabolise the medicine more slowly can have higher blood levels and may require dose adjustments.
If an injectable formulation is used, it is managed within specialist services and follows separate guidance. For the purposes of consumer education, this page focuses on oral treatment, which is the most common approach.
Overall, you may have been prescribed aripiprazole because its combination of stabilising effects and generally milder side-effect burden aligns well with your clinical needs.
How and when to take it
Most people take aripiprazole orally once a day. The dose is increased slowly to find the right balance between symptom improvement and tolerability. Your clinician may also consider your CYP2D6 genetic profile, because people who metabolise the medicine more slowly can have higher blood levels and may require dose adjustments.
If an injectable formulation is used, it is managed within specialist services and follows separate guidance. For the purposes of consumer education, this page focuses on oral treatment, which is the most common approach.
Overall, you may have been prescribed aripiprazole because its combination of stabilising effects and generally milder side-effect burden aligns well with your clinical needs.
Aripiprazole generally has a lighter side-effect profile than many antipsychotics, but effects still occur and vary between individuals.
Sleepiness or fatigue
Nausea or vomiting
Restlessness or difficulty sitting still
Headache
Mild dizziness
Low sodium levels (SIADH)
Impulse control behaviours such as gambling, overeating or compulsive shopping
Agitation or irritability
If anything feels unusual or out of character, especially around behaviour or motivation, it is important to discuss this with your clinician. Adjusting the dose can often resolve unwanted effects.
Explore PGX for Mental HealthAripiprazole has a comparatively long half-life, which means it stays in the body for several days and produces steady blood levels.
Oral bioavailability is high. Most people reach peak blood levels within a few hours.
Aripiprazole is metabolised mainly by two liver enzymes: CYP2D6 and CYP3A4. Both generate an active metabolite called dehydro-aripiprazole, which has similar properties to the original medicine and accounts for around 40 percent of total drug exposure.
People who are CYP2D6 poor metabolisers break down the medicine more slowly. This leads to higher blood concentrations and a longer half-life. Clinicians often use lower doses or slower titration schedules in such cases. Drug interactions that affect CYP2D6 or CYP3A4 can also influence blood levels.
The half-life of aripiprazole is long, typically around 75 hours, and even longer in poor metabolisers. The metabolite has a half-life of roughly 94 hours. These properties help maintain stable symptom control but mean that side effects may take time to resolve if the dose is too high.
Although there is currently no formal CPIC guideline for aripiprazole, clinical sources including the BNF and FDA note clear dosing differences for CYP2D6 poor metabolisers. This reflects how strongly genetic variation can influence aripiprazole exposure. Here are our practical takeaways:
Let your clinician know about any new medicines, especially antibiotics, SSRIs or herbal supplements such as St John’s Wort.
Share changes in behaviour, emotional tone or motivation, even if they seem subtle.
Pay attention to cardiovascular symptoms such as palpitations or dizziness.
Never hesitate to ask about adjusting the dose. Aripiprazole often needs personal tuning for best effect and lowest side-effect burden.
Other antipsychotics include:
Haloperidol
Olanzapine
Perphenazine
Thioridazine
Zuclopentixol
(1) https://www.ncbi.nlm.nih.gov/books/NBK535399/ (2) https://www.mdpi.com/2226-4787/12/3/92 (3) https://www.mdpi.com/2075-1729/15/6/830 (4) https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0319037 (5) https://www.researchgate.net/publication/355704819_Reduction_in_Absolute_Neutrophil_Counts_in_Patient_on_Clozapine_Infected_with_COVID-19/link/617bc54beef53e51e1ff566f/download?_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6Il9kaXJlY3QiLCJwYWdlIjoicHVibGljYXRpb24iLCJwcmV2aW91c1BhZ2UiOiJfZGlyZWN0In19 (6) https://pmc.ncbi.nlm.nih.gov/articles/PMC7947876/ (7) https://www.nature.com/articles/s41598-020-78474-0 (8) https://www.sciencedirect.com/science/article/pii/S0167527324001189 (9) https://www.researchgate.net/publication/369533176_Second_to_none_rationale_timing_and_clinical_management_of_clozapine_use_in_schizophrenia (10) https://www.mdpi.com/2227-9059/12/10/2294 (11) https://link.springer.com/article/10.1007/s40263-025-01236-x (12) https://pmc.ncbi.nlm.nih.gov/articles/PMC6449846/ (13) https://pmc.ncbi.nlm.nih.gov/articles/PMC8883353/ (14) https://www.mdpi.com/1422-0067/24/2/1243 (15) https://pmc.ncbi.nlm.nih.gov/articles/PMC8301879/ (16) https://bnf.nice.org.uk/ (17) https://www.nature.com/articles/s41380-023-02026-x (18) https://www.rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/adult-therapeutic-guidelines/mental-health/clozapine-initiation-and-re-titration-specialist-mental-health-guidelines/?utm_source=chatgpt.com (19) https://pmc.ncbi.nlm.nih.gov/articles/PMC7766585/ (20) https://pmc.ncbi.nlm.nih.gov/articles/PMC8061735/ (21) https://pmc.ncbi.nlm.nih.gov/articles/PMC4915939/ (22) https://www.sciencedirect.com/science/article/pii/S0378427425015802?via%3Dihub (23) https://www.ncbi.nlm.nih.gov/books/NBK547739/ (24) https://pmc.ncbi.nlm.nih.gov/articles/PMC9889418/ (25) https://pmc.ncbi.nlm.nih.gov/articles/PMC5725548/ (26) https://www.nature.com/articles/tp201794